Study Details

Open

High dose chemotherapy-Infusion of the patients own stem cells improves survival w/Peripheral T-cell

The purpose of this study is to compare the usual chemotherapy alone (observation) to using high dose chemotherapy followed by stem cell infusion after completing the usual chemotherapy. Treatment with high dose chemotherapy followed by stem cell transplant could prevent your lymphoma from returning.

Age & Gender

18 years ~ 75 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina, International (Colombia, Mexico)

What will be asked of you

If you decide to take part in this study, you will either be assigned to the observation group and be checked by your doctor and study team for every 6 months for 12 years after joining the study or you will be assigned to the treatment group (chemotherapy followed by infusion of your own stem cells) and be checked by your doctor and study team for every 6 months for 12 years after joining the study. If you are assigned to the observation group, then you will be observed. Your doctor and study team will check on you every 3 months for the first 2 years, then 6 months for 3 years, then annually for 6 years for a total of 12 years after joining the study. If you are assigned to the treatment group, then you would receive further chemotherapy, followed by infusion of your own stem cells. Your doctor and study team will check on you every 3 months for the first 2 years, then every 6 months for 3 years, then annually for 6 years for a total of 12 years after joining the study. After you finish your treatment, your doctor and study team will check you every 3 months for 2 years after treatment. After that, they will check you every 6 for 3 years.

Total length of participation:
48 months

Looking for Specific Volunteers

Able to participate:

Patient must be 18 to 75 years of age
Patient must have histologically proven peripheral T-cell lymphoma
Patient must have angioimmunoblastic T-cell lymphoma
Patient must have nodal PTCL with TFH phenotype
Patient must have achieved radiologic complete remission

Not eligible if:

If you are pregnant
Patient must be eligible for high dose chemotherapy and autologous stem cell transplant
Not have active infection requiring intravenous systemic
Not expect to conceive or father children

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Anne Beaven
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lymphoma)
Skin, Hair, and Nails

IRB Number

25-1875

ClinicalTrials.gov

NCT06724237